© Copyright 2020 – Drug Development and Therapeutics – All rights reserved.
Published by Scientific Scholar on behalf of Organization of Pharmaceutical Unity with BioAllied Sciences (OPUBS).
ISSN (Print): 2394-6555
ISSN (Online): 2394-2002
The Drug Development and Therapeutics (DDT) is an open-access peer-reviewed journal committed to publishing high-quality articles in the field of Drug synthesis and development and Therapeutics from industry, Clinicians and Academia. The journal is owned by the Organization of Pharmaceutical Unity with BioAllied Sciences (OPUBS) and published by the Scientific Scholar.
Our audience includes Drug Development and Therapeutics also including Natural products, Target validation, Targeted drug discovery, High-throughput screening, Combinatorial chemistry, and library design, Drug delivery, ADME/Tox, PK/PD, Pharmacology, Pharmaceutical formulation, Genomics and proteomics, molecular modeling, Bioinformatics, Vaccines, Clinical trial evaluations. Pharmaceutical sciences, medicinal/analytical sciences, Biotechnology, Bioallied Sciences.
DDT has a highly rigorous peer-review process that makes sure that manuscripts are scientifically accurate, relevant, novel and important. Authors disclose all conflicts, affiliations and financial associations such that the published content is not biased.
The editorial board comprises of a panel of experts from various disciplines of Medical and Bioallied sciences to provide their expertise and guidance in maintaining the clarity of content and focus of the purpose for the journal.
Raid Alany, PhD
Kingston University, London, UK
Hazrina Hadi, Ph.D
Faculty of Pharmacy,
International Islamic University of Malaysia
It is a peer-reviewed international journal with a double-blind review process. Its frequency of publication is quarterly. Currently, we only have E-Journal and do not publish in print.
An article published in the journal can be viewed without a fee by readers all over the world. The author also gets to retain copyright to the article and the figures. This allows authors to extend their exposure in the world of medical research and get worldwide recognition for their work.
The Drug Development and Therapeutics is committed to meeting and upholding the standards of ethical behavior at all stages of the publication process. We follow closely the industry associations, such as the Committee on Publication Ethics (COPE), International Committee of Medical Journal Editors (ICMJE) and World Association of Medical Editors (WAME), that set standards and provide guidelines for best practices in order to meet these requirements. For a summary of our specific policies regarding duplicate publication, conflicts of interest, patient consent, etc., please visit our Ethical Guidelines section
We have plagiarism check available on our Editors and Reviewer’s panel in the manuscript management system. We encourage our editors and reviewers to use the plagiarism check. Any manuscript with plagiarism will be rejected immediately.
This is an open-access journal, and articles are distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
Articles published online under the Ahead of Print model are considered published and can be cited and quoted using the DOI as the reference source. Drug Development and Therapeutics has a policy that changes will not be made after publication of an article without following accepted procedures for making corrections to the scientific record.
While advertisements are crucial to this journal to be able to keep all content free for everyone, ethical considerations are in place to ensure the integrity of the journal and its content are not biased or influenced by the advertisement.
“Pop-up” and “banner” advertisement appears at a fixed location on the page and does not interfere with the manuscript in any form.
The Editorial Board has full and final approval over the content of all advertisements.
Advertisers will never be shown any manuscripts or other content prior to publication.
Copies are provided free to members of the journal’s institution.
For non-members, please log on to https://scientificscholar.com/buy-subscriptions
Imaging Science Today was founded in 2011 by a group of practicing doctors and industry specialists, it changed its name to Scientific Scholar LLC, USA (https://scientificscholar.com). All the scientific journal publishing of Imaging Science Today was brought under the umbrella of Scientific Scholar LLC in 2017. Scientific Scholar LLC (https://scientificscholar.com) is a well-respected medical publisher that fully supports open access publishing models, Subscription and Society based journal models through its peer-review management system – EditorialAssist (https://journalmanagement.org). The head office of Scientific Scholar (https://scientificscholar.com) is in Rochester, NY, USA and has a subsidiary arm in India.
Scientific Scholar (https://scientificscholar.com) owns its Manuscript Management System called EditorialAssist (https://journalmanagement.org). This system is very intuitive with a very short learning curve. The overall functionality of this system is based on “DRAG AND DROP”.
The mission of the Scientific Scholar (https://scientificscholar.com) is “Share, Learn and Improve”.
Scientific Scholar (https://scientificscholar.com) currently publishes many prestigious and indexed journals like the Journal of Clinical Imaging Science (https://clinicalimagingscience.org), Surgical Neurology International (https://surgicalneurologyint.com), CytoJournal (https://cytojournal.com) and many more (https://scientificscholar.com/journals). Scientific Scholar (https://scientificscholar.com) currently publishes approximately thirty peer-reviewed journals.